{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:10:46Z","timestamp":1792609846456,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060027"],"award-info":[{"award-number":["82060027"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.intimp.2023.110058","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T01:28:09Z","timestamp":1681349289000},"page":"110058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis"],"prefix":"10.1016","volume":"119","author":[{"given":"Ninghong","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-0421","authenticated-orcid":false,"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2023.110058_b0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.intimp.2023.110058_b0010","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.intimp.2023.110058_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020407","article-title":"Multiple Myeloma: Available Therapies and Causes of Drug Resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.intimp.2023.110058_b0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2023.110058_b0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jdsr.2021.08.006","article-title":"Pathogenesis and treatment of multiple myeloma bone disease","volume":"57","author":"Hiasa","year":"2021","journal-title":"Jpn Dent Sci Rev"},{"issue":"1","key":"10.1016\/j.intimp.2023.110058_b0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2023.110058_b0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/bonekey.2012.135","article-title":"Mechanisms of multiple myeloma bone disease","volume":"1","author":"Galson","year":"2012","journal-title":"Bonekey Rep"},{"issue":"5","key":"10.1016\/j.intimp.2023.110058_b0040","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181245","article-title":"I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma","volume":"39","author":"Guo","year":"2019","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.110058_b0045","article-title":"Long Non-Coding RNAs in Multiple Myeloma. Noncoding","volume":"5","author":"Butova","year":"2019","journal-title":"RNA"},{"issue":"1","key":"10.1016\/j.intimp.2023.110058_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13237","article-title":"The role of long non-coding RNAs in multiple myeloma","volume":"103","author":"Cui","year":"2019","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110058_b0055","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/s41375-021-01147-y","article-title":"Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma","volume":"35","author":"Carrasco-Leon","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.intimp.2023.110058_b0060","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00382-19","article-title":"Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152\u20133p","volume":"40","author":"Zheng","year":"2020","journal-title":"Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110058_b0065","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41419-018-1219-0","article-title":"LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p","volume":"10","author":"Pan","year":"2019","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.intimp.2023.110058_b0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14715\/cmb\/2020.66.6.14","article-title":"Long noncoding RNA H19 promotes vincristine resistance in multiple myeloma by targeting Akt","volume":"66","author":"Wang","year":"2020","journal-title":"Cell. Mol. Biol. (Noisy-le-Grand)"},{"key":"10.1016\/j.intimp.2023.110058_b0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cca.2018.02.019","article-title":"Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma","volume":"480","author":"Pan","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.intimp.2023.110058_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001803","article-title":"Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche","volume":"9","author":"Muller","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2023.110058_b0085","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41417-020-0176-9","article-title":"Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4\u20131BB and\/or CD40","volume":"27","author":"Wenthe","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"8","key":"10.1016\/j.intimp.2023.110058_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081976","article-title":"The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma","volume":"13","author":"Carrasco-Leon","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2023.110058_b0095","doi-asserted-by":"crossref","first-page":"18079","DOI":"10.1038\/s41598-017-18056-9","article-title":"Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-kappaB pathway","volume":"7","author":"Sun","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2023.110058_b0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/1535-7163.MCT-15-0943","article-title":"High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro","volume":"15","author":"Wang","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.intimp.2023.110058_b0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41416-018-0196-5","article-title":"MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1\/P-ERK axis","volume":"119","author":"Zhai","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2023.110058_b0110","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fphar.2019.00940","article-title":"MicroRNA-532-3p Suppresses Malignant Behaviors of Tongue Squamous Cell Carcinoma via Regulating CCR7","volume":"10","author":"Feng","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110058_b0115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41388-018-0440-8","article-title":"KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin\/AKT signaling","volume":"38","author":"Han","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2023.110058_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111171","article-title":"Estrogen promotes lncRNA H19 expression to regulate osteogenic differentiation of BMSCs and reduce osteoporosis via miR-532-3p\/SIRT1 axis","volume":"527","author":"Li","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110058_b0125","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbrc.2020.02.126","article-title":"miR-532-3p inhibits osteogenic differentiation in MC3T3-E1 cells by downregulating ETS1","volume":"525","author":"Fan","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"24","key":"10.1016\/j.intimp.2023.110058_b0130","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1038\/sj.emboj.7600481","article-title":"The E2F family: specific functions and overlapping interests","volume":"23","author":"Attwooll","year":"2004","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.intimp.2023.110058_b0135","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41416-020-01032-y","article-title":"E2F7-EZH2 axis regulates PTEN\/AKT\/mTOR signalling and glioblastoma progression","volume":"123","author":"Yang","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2023.110058_b0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/aps.2013.161","article-title":"EZH2: biology, disease, and structure-based drug discovery","volume":"35","author":"Tan","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.intimp.2023.110058_b0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110058_b0150","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"issue":"41","key":"10.1016\/j.intimp.2023.110058_b0155","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1038\/sj.onc.1208771","article-title":"The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype","volume":"24","author":"Croonquist","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2023.110058_b0160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-018-0148-5","article-title":"EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies","volume":"6","author":"Tremblay-LeMay","year":"2018","journal-title":"Biomark Res"},{"issue":"35","key":"10.1016\/j.intimp.2023.110058_b0165","doi-asserted-by":"crossref","first-page":"7635","DOI":"10.1523\/JNEUROSCI.0538-18.2018","article-title":"EZH2 Methyltransferase Activity Controls Pten Expression and mTOR Signaling during Fear Memory Reconsolidation","volume":"38","author":"Jarome","year":"2018","journal-title":"J. Neurosci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692300379X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692300379X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:20:01Z","timestamp":1785770401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692300379X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"alternative-id":["S156757692300379X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110058","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110058"}}